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Abstract
Background: Standard radiotherapy is the treatment of first choice in patients with symptomatic spinal metastases,
but is only moderately effective. Stereotactic body radiation therapy is increasingly used to treat spinal metastases,
without randomized evidence of superiority over standard radiotherapy. The VERTICAL study aims to quantify the
effect of stereotactic radiation therapy in patients with metastatic spinal disease.
Methods/design: This study follows the ‘cohort multiple Randomized Controlled Trial’ design. The VERTICAL study
is conducted within the PRESENT cohort. In PRESENT, all patients with bone metastases referred for radiation
therapy are enrolled. For each patient, clinical and patient-reported outcomes are captured at baseline and at
regular intervals during follow-up. In addition, patients give informed consent to be offered experimental
interventions. Within PRESENT, 110 patients are identified as a sub cohort of eligible patients (i.e. patients with
unirradiated painful, mechanically stable spinal metastases who are able to undergo stereotactic radiation therapy).
After a protocol amendment, also patients with non-spinal bony metastases are eligible. From the sub cohort, a
random selection of patients is offered stereotactic radiation therapy (n = 55), which patients may accept or refuse.
Only patients accepting stereotactic radiation therapy sign informed consent for the VERTICAL trial. Non-selected
patients (n = 55) receive standard radiotherapy, and are not aware of them serving as controls. Primary endpoint is
pain response after three months. Data will be analyzed by intention to treat, complemented by instrumental
variable analysis in case of substantial refusal of the stereotactic radiation therapy in the intervention arm.
(Continued on next page)
* Correspondence: J.M.vanderVelden@umcutrecht.nl
1Department of Radiation Oncology, University Medical Center Utrecht,
Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
van der Velden et al. BMC Cancer  (2016) 16:909 
DOI 10.1186/s12885-016-2947-0
(Continued from previous page)
Discussion: This study is designed to quantify the treatment response after (stereotactic) radiation therapy in
patients with symptomatic spinal metastases. This is the first randomized study in palliative care following the
cohort multiple Randomized Controlled Trial design. This design addresses common difficulties associated with
classic pragmatic randomized controlled trials, such as disappointment bias in patients allocated to the control arm,
slow recruitment, and poor generalizability.
Trial registration: The Netherlands Trials Register number NL49316.041.14. ClinicalTrials.gov registration number
NCT02364115. Date of trial registration February 1, 2015.
Keywords: VERTICAL trial, Randomized controlled trial, Cohort multiple Randomized Controlled Trial design, Spinal
metastases, Bone metastases, Pain, Stereotactic body radiotherapy
Background
Bone metastases are a frequent distant manifestation of
cancer, with the spinal column being the most common
site [1]. Spinal metastases can induce cancer-related pain,
mechanical instability, and neural compression, thereby
causing morbidity and impacting on quality of life (QOL).
Treatment is aimed at pain relief and prevention of neuro-
logical deficits. The treatment for most patients with
symptomatic spinal metastases is standard external beam
radiotherapy [2], which is moderately effective: around
60% of patients who undergo external beam radiotherapy
experience pain relief [3]. Furthermore, pain relief is often
incomplete with complete pain response rates ranging
from 0 and 23% [3] and one in five patients needs re-
irradiation [4]. Escalating the dose to the metastatic site
might improve the pain response and prolong the dur-
ation of pain relief [5]. Dose escalation to spinal tumors
using standard radiotherapy is complicated by the low tol-
erance of the spinal cord to radiation. Stereotactic body
radiotherapy (SBRT) is able to deliver precise high-dose
radiation to spinal metastases in single or multiple frac-
tions, while sparing surrounding healthy tissues. Phase I
and II studies have suggested that, for selected groups of
patients, SBRT for spinal metastases may be accurate, safe,
and effective [5, 6], with complete pain response in 54% of
patients six months after SBRT [7]. Other authors even re-
ported overall pain response rates around 90% [8–10]. To
date however, no randomized controlled studies have been
performed so equipoise still exist on the effectiveness of
SBRT in comparison to standard radiotherapy. Therefore,
we designed a pragmatic randomized controlled trial to
compare conVEntional RadioTherapy with stereotactIC
body radiotherapy in patients with spinAL metastases
(VERTICAL) following the CONSORT statement [11].
Methods/design
Study design
This study is conducted within the Prospective Evalu-
ation of interventional StudiEs on boNe meTastases
(PRESENT) cohort [12]. All patients with bone metasta-
ses referred to the departments or radiation oncology or
orthopedic surgery of the University Medical Center
Utrecht are asked to participate in this prospective, obser-
vational cohort. Baseline and follow-up data are collected
from clinical files, and patient-reported outcomes (PROMs,
i.e. a pain inventory and QOL questionnaires) are collected
at fixed time intervals. This study follows the cohort
multiple randomized controlled trial (cmRCT) design
as described by Relton and colleagues [13].
Patient recruitment
At enrollment, patients give informed consent for collec-
tion of clinical and survival data, and can opt-in to provide
PROMs. In addition, in a separate question, we ask pa-
tients for their broad consent for future randomization in
trials that will investigate the effectiveness of experimental
treatments [14]. Patients within the PRESENT cohort who
meet the VERTICAL inclusion criteria (Table 1) are iden-
tified as a sub cohort of eligible patients. Eligible patients
are PROMs-providing participants of the PRESENT co-
hort, have untreated symptomatic spinal metastases, and
have given consent for broad randomization to experi-
mental interventions. Patients are excluded if they are not
able to undergo SBRT, have severe or progressive neuro-
logical deficits, received previous radiotherapy or surgery
to the index site(s), or have a life expectancy less than
three months. After a protocol amendment on September
23, 2015 to adjust to developments in clinical practice, also
patients with non-spinal bony metastases are eligible.
Random selection
Eligible patients are randomly selected from the sub co-
hort on a 1:1 basis with varying block sizes (n = six or
eight) using an in-house randomization computer pro-
gram. The radiation oncologist will offer the experimental
intervention (i.e. SBRT) to the randomly selected patients.
If they accept the treatment offer, they will sign informed
consent for participation in the VERTICAL study. Patients
who refuse the SBRT will receive care as usual (i.e. stand-
ard radiotherapy). According to the cmRCT design, pa-
tients in the sub cohort who are not randomly selected
will not be informed about the experimental intervention,
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nor will they be informed about their participation in the
control arm of the VERTICAL study. Outcomes in ran-
domly selected patients are compared with the outcomes
in eligible patients not randomly selected who received
standard radiotherapy (Fig. 1).
Standard radiotherapy
Standard radiotherapy for symptomatic bony metastases
consists of single fraction external beam radiotherapy of
8 Gray (Gy). The radiation oncologist might however
choose a multi-fraction regime of 30 Gy in 10 fractions
if the patient has a favorable primary tumor (i.e. breast
or prostate cancer), a Karnofsky performance score (KPS)
of 80–100%, and absence of visceral or brain metastases.
The radiation dose distribution usually consists of a single
field in posteroanterior direction with the normalization
point (100% isodoseline) at 6 cm for a 6 MV photon beam
and at 6 or 7 cm for a 10 MV photon beam. The vertebral
Table 1 Selection criteria for the VERTICAL study
Inclusion criteria Exclusion criteria
Participant in PRESENT cohort Lesion in C1, and C2
Filling out PRESENT-questionnaires Contraindication for MRI if MRI is indicated
Broad consent for randomization to experimental interventions Radiosensitive histology such as multiple myeloma
Histologic proof of malignancy Unable to undergo SBRT treatment
Imaging evidence of bone metastases Patient with < 3 months life expectancy
For spinal lesions, per lesion no more than 3 consecutive spine segments
involved with one unaffected vertebral body above and below
Chemotherapy or systemic radionuclide delivery within 24 h before
and after SBRT
No more than 2 painful lesions needing treatment Previous EBRT or SBRT to same level
For spinal lesions, no compression of spinal cord For spinal lesions, unstable spine requiring surgical stabilization
No or mild neurological signsa Severe, worsening or progressive neurological deficit
KPS > 50 and pain score > 3b
VERTICAL randomized controlled trial comparing conVEntional RadioTherapy with stereotactIC body radiotherapy in patients with spinAL metastases;
PRESENT Prospective Evaluation of interventional StudiEs on boNe meTastases (PRESENT) cohort; MRI magnetic resonance imaging; SBRT stereotactic body
radiotherapy; EBRT external beam radiotherapy; KPS Karnofsky performance score
aradiculopathy, dermatomal sensory change, and muscle strength of involved extremity is Medical Research Counsil (MRC) 4/5
bon a scale from 0 to 10
Fig. 1 Study design VERTICAL study A large observational cohort of patients with bone metastases is recruited and their outcomes regularly
measured (dark blue box). Patients within the PRESENT cohort who meet the VERTICAL inclusion criteria are identified as a sub cohort of eligible
patients (light blue box). Randomly selected patients (orange box) are offered the SBRT intervention. The outcomes of these randomly selected
patients (i.e. the intervention arm) are then compared with the outcomes of eligible patients not randomly selected who receive standard of care
(i.e. the control arm, brown boxes)
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body should at least receive 80% of the prescribed dose. If
necessary, a field in anteroposterior direction is added to
the posteroanterior field. Metastases in the cervical spine
are usually treated with two lateral opposing fields. The
leafs of the multileaf collimator are used to adjust the
shape of the treatment field. Prior to treatment, cone
beam computed tomography (CBCT) scan images are ob-
tained to verify that the position of the patient is correct
with regard to the planning computed tomography (CT).
Currently, our department is working on the clinical
implementation of auto-planning for single fraction
treatment of patients with bone metastases. Automatic
treatment plans will then be delivered to the spinal metas-
tases using intensity-modulated radiation therapy (IMRT)
technique.
Stereotactic body radiotherapy
Patients in the experimental arm undergoing SBRT are
immobilized with an S-frame thermoplastic mask in case
of skull or cervical spine tumors extending to the upper
thoracic (T3) vertebral body. In case of lower thoracic
and lumbar lesions, and rib and pelvic lesions, they are
immobilized using a vacuum mattress (BlueBAG™, Elekta,
Stockholm, Sweden). Magnetic resonance imaging (MRI)
is used to delineate the gross tumor volume (GTV), clin-
ical target volume (CTV), and the organs at risk (OAR).
We use MRI guidance to deliver stereotactic radiotherapy
to the visible metastasis (i.e. GTV) exclusively. With the
aid of T1 weighted, T2 weighted, and diffusion weighted
imaging (DWI) sequences, it is possible to delineate the
GTV accurately [15, 16]. Adjacent normal appearing bone
may harbor subclinical disease and could potentially serve
as a source for a local recurrence [17]. Therefore, the bony
compartment containing the GTV (i.e. the CTV, which
consists of the entire vertebral body, pedicle, transverse
process, lamina, or spinous process) is prescribed 8 Gy in
order to treat subclinical disease whereas the metastasis
receives 18 Gy (Fig. 2). This simultaneous integrated boost
approach has the potential advantage of lowering the risk
of vertebral compression fractures by sparing the un-
affected, healthy bone tissue surrounding the metastasis
while also treating subclinical disease. When necessary, an
equivalent dose may be given using another fractionation
schedule: 30 Gy in three fractions to the visible metastasis
with 15 Gy in three fractions to the bony compartment or
35 Gy in five fractions with 20 Gy in five fractions to
the bony compartment. Possible reasons to fractionate
the dose might be proximity of visible metastasis to the
spinal cord or more than two consecutive spine segments
involved. Treatment planning is performed on pre-
treatment CT and MRI scans that are co-registered to
yield information on all relevant structures for assessing
dose distribution. Volumetric modulated arc therapy
(VMAT) treatment plans are generated for SBRT patients.
Dose constraints are set for the OAR based on institution
specific guidelines. These constraints, and particularly the
constraint of the spinal cord, are of primary concern. If
necessary, dose deliverance to the GTV will be limited in
order to meet these constraints [18]. For all patients, an
online CBCT scan is acquired with the patient in treat-
ment position on the treatment couch just before start of
the irradiation. The CBCT scan yields the exact position
of the bony anatomy and is registered to the pre-
treatment CT and MRI data. The alignment of the patient,
or more specifically the affected vertebra bodies, on the
CBCT scan is compared with the pre-treatment CT and
MRI scans. After possible correction a second CBCT is
performed between the two VMAT arcs. A third CBCT is
taken post-treatment to document stability of the target
during treatment.
Primary endpoint
Primary endpoint of this study is complete or partial
pain response at three months. Pain response is defined
according to the International Bone Metastases Consen-
sus Endpoints for Clinical Trials (Table 2) [19]. A pain
score of zero with no concomitant increase in analgesic
intake compared to baseline is defined as complete re-
sponse. Partial response is pain reduction of at least two
points on a scale of 0–10 without increase in analgesic
intake and/or analgesic reduction of at least 25% from
baseline without an increase in pain. Pain progression is
defined as an increase in pain score of at least two
points above baseline with stable analgesic use and/or as
Fig. 2 Standard radiotherapy and stereotactic body radiotherapy Comparison of a conventional radiation dose distribution using standard
radiotherapy (left) with a spinal stereotactic radiotherapy simultaneous integrated boost distribution (right) in a patient with a T4 vertebral body
metastasis from breast cancer
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an increase of at least 25% in analgesic use compared to
baseline with at least stable pain scores. All responses
not captured with complete and partial response or pain
progression are considered indeterminate response. Pain
is measured by the Brief Pain Inventory (BPI), which has
been validated for use in advanced cancer patients to
assess pain and functional interference stemming from
bone metastases [20].
Secondary endpoints
Secondary endpoints include local tumor control, dur-
ation of pain response, toxicity, vertebral compression
fractures, QOL, and overall survival. Evaluation of local
tumor control will be based on imaging acquired during
follow-up. Duration of pain response starts at response
until pain progression or end of follow-up using informa-
tion provided by the BPI. A radiation oncologist records
toxicity according to the National Cancer Institute’s
Common Terminology Criteria for Adverse Events, ver-
sion 4.0 [21] six weeks after radiation treatment. Toxicity
occurring after 6 weeks, (serious) adverse events (SAEs),
and hospitalization are registered in the context of the
PRESENT cohort. Information about toxicity is based on
clinical follow-up data and biannual patient-administered
questionnaires on health status and hospitalization. All pa-
tients in the SBRT arm undergo an additional MRI scan
six months after radiation in order to assess vertebral
compression fractures. Since most compression fractures
occur four months after radiation treatment [22], this 6-
month-MRI captures most incidents. In case of clinical
suspicion of a vertebral compression fracture, obtaining
the MRI scan will be advanced as deemed appropriate.
Quality of life is measured by the EORTC QLQ-C15-PAL
general questionnaire [23] and the bone metastases-
specific module, the EORTC QLQ-BM22 [24]. The
EORTC QLQ-C15-PAL is an abbreviated 15-item version
of the EORTC QLQ-C30 specially developed for use in
palliative care. In order to evaluate the cost-effectiveness,
patients are also provided with the EQ-5D questionnaire.
Patients fill out these QOL questionnaires and the BPI
before the start of radiation treatment (baseline) and after
one, two, three, and six months, and every six months
thereafter. The BPI is provided after two and six weeks
as well. We make use of the digital patient tracking sys-
tem PROFILES, so patients are able to complete the
questionnaires online after secured login [25]. Overall
survival is monitored within the PRESENT cohort by
clinical follow-up and via an electronic link with the
Municipal Personal Records Database.
Safety
We will report treatment induced SAEs within 15 days
following notification through a government based inter-
net portal to the accredited institutional review board
that approved the protocol. Treatment induced SAEs that
result in death or are life threatening will be reported
within seven days.
Sample size considerations
Based on the most recent meta-analysis, we expect a
pain response in 60% of patients following standard
radiotherapy [3]. Pain response after stereotactic radio-
therapy is assumed to be 85% [8, 9]. We expect that ap-
proximately 90% of patients who are offered SBRT
treatment, will accept the offer. Cross-over from control
arm to the SBRT treatment arm is extremely unlikely,
since only patients who are randomly selected to receive
SBRT are informed about the treatment. Taking a one-
sided α of 5% and a power of 80%, we require 49 patients
per treatment arm to show a statistically significant differ-
ence of 15% in pain response. The reason to choose a one
sided α is that, although improbable, inferior pain re-
sponse after stereotactic treatment would lead to the same
action as no difference at all between the two treatment
regimen. This is because the SBRT treatment will only be
implemented if it is significantly better than the usual care,
since SBRT treatment is more complex, less convenient
for patients, and more expensive than standard radiother-
apy. Finally, to allow for a 10% drop out rate, recruitment
of 55 patients per group is intended. We expect to
complete recruitment within 18 months based on the
number of patients we treat in our center annually.
Data analysis
Data will be analyzed according to the intention to treat
principle. Data of eligible patients who were randomly
offered stereotactic radiotherapy will be compared with
eligible patients who were not randomly selected and
received standard radiotherapy. In case of dropout (i.e.
patients not surviving longer than three months or pa-
tients unable to provide pain scores and analgesic use),
a worst-case analysis will be performed: dropped-out
patients will be classified as non-responders. In case of
substantial refusal of the SBRT offer in the intervention
Table 2 Response rate to radiotherapy according to the
international consensus [19]
Responders
Complete response Pain score of 0 and stable or reduced OMED
Partial response Pain reduction of 2 points on a 0–10 scale or
more and/or OMED reduction by 25% or more
Non-responders
Pain progression Increase of 2 points on a 0–10 scale or more above
baseline, and/or OMED increased by 25% or more
Indeterminate
response
Any response including stable disease that is not
captured by complete or partial response or pain
progression
OMED daily oral morphine equivalent
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arm, instrumental variable analysis will be used to account
for non-compliance [26]. The primary outcome (i.e. pro-
portion of patients with response to radiotherapy) will be
presented in absolute numbers and proportions. Differ-
ences in pain response will be compared by χ2 test. If
randomization fails, imbalances between baseline charac-
teristics will be adjusted by logistic regression analysis. Dif-
ferences in duration of response and overall survival will
be analysed by Kaplan-Meier analysis and log rank test.
Toxicity will be presented as the overall incidence of grade
3–4 toxicity and incidence of vertebral compression frac-
tures. Differences will be tested with the χ2 test. A com-
parison in QOL will be made between the baseline QOL
and at predefined intervals after treatment. A change of
10% of the scale breadth will be considered a clinically
relevant change of QOL [27]. Data will be presented as
improved (≥10% increase), stable, or worsened (≥10%
decrease) QOL. We will evaluate the pattern of QOL as
a continuous outcome over time using mixed models.
Differences with a P-value <0.05 will be considered statis-
tically significant. We have planned to perform an interim
analysis after inclusion of half of the patients (i.e. 55 pa-
tients) when they have completed their follow up (i.e.
three months pain assessment).
Discussion
In this report, we present the rationale and design of the
VERTICAL trial. In this randomized study, we investi-
gate whether SBRT can increase the proportion of pa-
tients with (complete or partial) pain response. Although
standard radiotherapy is moderately effective in achiev-
ing pain relief in most patients with spinal metastases,
up to 40% of patients do not experience any pain relief
and complete response occurs in only 30% of responders
[3]. Presently, it is not exactly understood why some pa-
tients do not respond (adequately) to standard radiother-
apy. A factor that may play a role in the suboptimal
response to standard radiotherapy is the way the radiation
dose is delivered. Barton and colleagues [28] showed that
the dose received by the vertebral column using standard
radiation techniques varies by up to 50%. For instance,
when using a direct posteroanterior field to deliver 8 Gy at
a depth of 5 cm, metastases located in deep vertebrae re-
ceive less than 50% of the prescribed dose. This is import-
ant, since 4 Gy in one fractions is proven to be less
effective than 8 Gy [29–31]. If there is indeed a threshold
dose below which pain relief is less likely and of slower
onset, it may be important to ensure that the vertebral
metastasis receives the dose intended. However, the
low tolerance of the spinal cord to radiation limits the
standard radiation dose to a level that below the opti-
mal therapeutic dose thus providing a less than optimal
response. Precise confinement of the radiation dose, even
including dose escalation in addition, should increase the
probability of pain relief while the risk of injury to the
spinal cord is minimized. Several retrospective and pro-
spective phase II studies have indeed shown the safety and
efficacy of SBRT in spinal metastases [5, 6].
Most studies on spinal SBRT included a heterogeneous
patient population, including previously unirradiated
patients, patients who needed reirradiation, and post-
operative SBRT, and these categories include patients
with or without solitary spine metastases [8, 32]. We
include all unirradiated patients with spinal metastases
including patients with diffuse metastases, and mild
neurological complaints. In this way, we deliberately chose
a pragmatic approach since we expect that this would be
the patient population that is going to be treated once the
benefits of SBRT would have been established. In order to
investigate the effect of SBRT without the effect of add-
itional treatments, we however exclude patients who re-
ceived previous standard or stereotactic body radiotherapy
or surgery to the index site. As pragmatic trials investigate
the effectiveness of medical treatment strategies under
usual conditions, the standard strategy (i.e. 8 Gy in a single
fraction, or for selected patients 30 Gy in 10 fractions) will
be compared to the SBRT strategy (which includes more
dose schedules). Still, the biological effective dose (BED) of
the three dose regimen is much higher compared to the
BED of the conventional dose regimen. If there is a differ-
ence in pain response after SBRT compared to standard
radiotherapy, we should be able to detect that differences
despite the use of multiple radiation dose schedules. Trad-
itionally, stereotactic radiotherapy in metastatic bone dis-
ease is intended for patients with spinal metastases.
However, SBRT is increasing being applied in the treat-
ment of non-spine osseous metastases [33]. Since spinal
metastases are similar to non-spine osseous metastases in
terms of bone involvement and pain relief after standard
radiotherapy [34, 35], the response after SBRT in spinal
and non-spine osseous metastases is likely to be similar as
well. Therefore, we have extended the VERTICAL inclu-
sion criteria to patients with non-spinal bony metastatic
disease.
To our knowledge, six other randomized studies on
spinal SBRT are currently being conducted (Table 3)
[36–41]. Only two other trials require both CT and MRI
imaging for the delineation of the spinal metastases [37,
38], however, these trials delineate the whole bony com-
partment (i.e. the CTV) that contains the metastasis in-
stead of using an simultaneous integrated boost approach.
They also have strict instructions on how to apply the
standard and stereotactic body radiotherapy in contrast to
our more pragmatic approach, offering radiation oncolo-
gists leeway in fractionation schedule. Furthermore, the
VERTICAL trial distinguishes itself from these trials by
applying the cmRCT design. The cmRCT design was
proposed as a variant of classic pragmatic randomized
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Table 3 Randomized trials on SBRT for spinal metastasesa
Name, institution Start date, sample
size
Patients SBRT treatment Comparator Primary Endpoint
Mahadevan et al. [36]
Beth Israel Deaconess MC
01–2012
81
Number of sites not stated; Pain≥ 5;
No rapid neurologic decline
Total dose unknown in 1, 3, or
5 fractions; No more information
provided





Number of sites not stated; May
have other visceral metastases;
Pain ≥ 5;
No neurologic deficit
Any modern system; 20 Gy in one
fraction; Delineation with MRI and CT;
Target volume is GTV, with bony CTV
expansion, PTV margin≤ 3 mm
Standard EBRT single dose of
8 Gy, no restrictions to radiation
technique
Pain response taking administration





Up to 3 spinal sites; May have other
visceral metastases; Pain ≥ 5; No
rapid neurologic decline
IMRT or other dose painting technique;
16 or 18 Gy in one fraction; Delineation
with MRI and CT; Target volume is
involved VB
Standaard EBRT single dose of
8 Gy, 2D and 3D conformal
therapy
Pain response (increase or decrease





Up to 2 spinal sites; No neurologic
deficit
IMRT; 24 Gy in one fraction; Delineation
with CT; Target volume is involved VB
with PTV margin
Standard EBRT 30 Gy in 10
fractions, 3D conformal planning
Pain response (increase or decrease
of > 2 points) at 3 months




Number of sites not stated; May
have other visceral metastases;
No rapid neurologic decline
36 Gy in 12 fractions plus integrated
boost 48 Gy in 12 fractions; No
more information provided
Conventional EBRT 30 Gy in
10 fractions
Tumor control defined as time to
progression on MRI
Tingting et al. [41] Cancer
Hospital of Shantou UMC
03–2014
100
Up to 3 spinal sites 24 Gy in 2 fractions; No more
information provided
Conventional EBRT 30 Gy in 1
0 fractions
Pain response taking administration






Up to 2 spinal sites; May have
other visceral metastases; Pain≥ 3;
no rapid neurologic decline
VMAT; 18 Gy in one fraction or
fractionated equivalent; Delineation
with MRI and CT; Target volume with
simultaneous integrated
boost
Standard of care for standard
radiotherapy
Pain response (increase or decrease
of≥ 2 points) taking administration
of opioid into account at 3 months
CT computed tomography, CTV clinical target volume, EBRT external beam radiotherapy, IMRT image guided radiotherapy, GTV gross tumor volume, MC medical center, MRI magnetic resonance imaging, PTV planning
target volume, VB vertebral body
aExcluding studies on oligometastases including spinal oligometastatic disease, comparing surgery with SBRT, and studies including non-spinal lesions as well













controlled trials (RCTs) and addresses some common
difficulties associated with those RCTs, such as disap-
pointment bias, drop-outs, slow recruitment, and poor
generalizability [13]. Patients and doctors often have a
strong preference for the experimental treatment that
has not proven to, but is expected to be superior. In-
vestigators of the RTOG 0631 trial indeed experience
that patients and their physicians prefer the SBRT
treatment over standard radiotherapy [Samuel Ryu, per-
sonal communication]. Consequently, patients allocated
to the standard arm may show disappointment when
reporting outcomes. This is of particular concern since
the primary endpoint consists of a subjective outcome
(i.e. pain scores). By using the cmRCT design however,
control patients are unaware of being allocated to the
control arm, which will prevent disappointment bias in
observed outcomes. Furthermore, standard of care is
likely to be unaffected by treatment allocation and will
therefore better resemble routine practice. We also ex-
pect lower drop-outs rates since patients in the control
arm are not likely to withdraw from standard care,
which may be of particular interest in this fragile pa-
tient population. Because of this fragility, researchers in
this field should make an effort to optimize recruitment
rates. The use of the cmRCT design may foster recruit-
ment rates by its unique informed consent procedure.
A reason not to take part in classic randomized studies
might be that patients cannot be guaranteed to receive
the desired experimental treatment. Furthermore, once
participating, patients are often allowed to participate
in one trial at a time only. By contrast, patients partici-
pating in a cmRCT study give broad informed consent
to participate in randomized trials, but not to specific
trials which may increase recruitment rates. Moreover,
the cmRCT cohort offers an infrastructure which allows
the conduct of randomized trials simultaneously. Fi-
nally, recruitment in cohort studies is usually more
manageable compared with recruitment in RCTs. The
inclusion rates in the PRESENT cohort for example are
promising: the participation rate is 83%, and 88% of the
participating patients have given informed consent for
broad randomization to experimental interventions.
The use of a cohort in cmRCT studies offers more po-
tential advantages. Palliative patients willing to partici-
pate in randomized trials often represent a relatively
healthier and higher-educated subgroup. By using a co-
hort as a recruitment pool for RCTs, a more routine
population is included since recruitment for cohort
studies is generally less selective. Moreover, the cohort
provides information on baseline characteristics and
outcome measurements (i.e. the regular cohort mea-
sures) of drop-outs, which is essential in the data ana-
lysis. Patients allocated to the control arm, are cohort
participants who receive the current standard of care
(i.e. standard radiotherapy in the PRESENT case). In
our department, the standard of care for patients with
bone metastases will change from standard radiother-
apy to automatically generated conformal treatment
plans. Would the VERTICAL trial have been conven-
tionally conducted, this could have been problematic
since control patients in the VERTICAL trial would
then have been withhold from standard of care. However,
the cmRCT design has the advantage that experimental
interventions are compared with the most up-to-date
standard of care, instead of competing with outdated treat-
ments, which is often the case in completed classic RCTs.
Finally, a valuable feature of the cmRCT design is the op-
portunity to evaluate and quantify the acceptance rates of
the offered treatment (i.e. SBRT). This offers new insights
into patient preferences and reasons for refusal of SBRT.
We feel that prevention of disappointment bias, more effi-
cient and less selective patient recruitment, up-to-date
standard of care, and quantifying patients’ preference
could significantly improve trials conducted according to
the cmRCT design.
In conclusion, the VERTICAL study is a pragmatic
randomized trial, following the cmRCT design, which
compares stereotactic radiotherapy with standard radio-
therapy in patients with spinal metastases in terms of
pain response, with the ultimate goal to improve quality
of life.
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with spinAL metastases; VMAT: Volumetric modulated arc therapy
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